B. Riley Analysts Lift Earnings Estimates for ETON

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – Investment analysts at B. Riley lifted their Q2 2025 earnings estimates for Eton Pharmaceuticals in a research report issued to clients and investors on Wednesday, July 16th. B. Riley analyst M. El-Saadi now expects that the company will post earnings per share of ($0.01) for the quarter, up from their prior estimate of ($0.04). B. Riley currently has a “Buy” rating and a $26.00 price target on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.14) per share. B. Riley also issued estimates for Eton Pharmaceuticals’ FY2025 earnings at $0.52 EPS, FY2028 earnings at $2.25 EPS and FY2029 earnings at $2.51 EPS.

Eton Pharmaceuticals (NASDAQ:ETON) last released its earnings results on Tuesday, May 13th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.02). Eton Pharmaceuticals had a negative return on equity of 3.15% and a negative net margin of 9.49%. The company had revenue of $17.28 million during the quarter, compared to analysts’ expectations of $14.33 million.

A number of other analysts have also weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price objective (up from $33.00) on shares of Eton Pharmaceuticals in a research note on Thursday, May 29th. Craig Hallum upped their price objective on shares of Eton Pharmaceuticals from $26.00 to $28.00 and gave the stock a “buy” rating in a research note on Wednesday, May 14th.

Eton Pharmaceuticals Trading Up 7.7%

ETON stock opened at $15.02 on Monday. The company has a quick ratio of 1.43, a current ratio of 1.97 and a debt-to-equity ratio of 1.23. Eton Pharmaceuticals has a twelve month low of $3.25 and a twelve month high of $21.48. The stock has a market capitalization of $402.84 million, a price-to-earnings ratio of -83.44 and a beta of 1.18. The firm’s fifty day simple moving average is $16.14 and its two-hundred day simple moving average is $15.33.

Hedge Funds Weigh In On Eton Pharmaceuticals

Several institutional investors have recently bought and sold shares of the company. Acadian Asset Management LLC grew its position in shares of Eton Pharmaceuticals by 61.9% during the first quarter. Acadian Asset Management LLC now owns 402,428 shares of the company’s stock worth $5,219,000 after buying an additional 153,923 shares in the last quarter. Jane Street Group LLC grew its position in shares of Eton Pharmaceuticals by 49.1% during the first quarter. Jane Street Group LLC now owns 95,919 shares of the company’s stock worth $1,245,000 after buying an additional 31,596 shares in the last quarter. Goldman Sachs Group Inc. grew its position in shares of Eton Pharmaceuticals by 34.9% during the first quarter. Goldman Sachs Group Inc. now owns 175,220 shares of the company’s stock worth $2,274,000 after buying an additional 45,341 shares in the last quarter. Millennium Management LLC lifted its stake in Eton Pharmaceuticals by 156.3% during the first quarter. Millennium Management LLC now owns 355,929 shares of the company’s stock worth $4,620,000 after purchasing an additional 217,042 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. purchased a new stake in Eton Pharmaceuticals during the first quarter worth approximately $704,000. 27.86% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Eton Pharmaceuticals news, insider David Krempa sold 16,977 shares of the firm’s stock in a transaction on Thursday, June 12th. The stock was sold at an average price of $14.92, for a total value of $253,296.84. Following the completion of the sale, the insider directly owned 629,669 shares of the company’s stock, valued at $9,394,661.48. This trade represents a 2.63% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last 90 days, insiders sold 34,000 shares of company stock valued at $504,318. Company insiders own 14.89% of the company’s stock.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.